EXOC8: The Drug Target of the Future? (G149371)

Target Name: EXOC8

NCBI ID: G149371

EXOC8

EXOC8: The Drug Target of the Future?

Introduction

Exocyst complex 84-kDa subunit (EXOC8) is a protein that plays a crucial role in the structure and function of the endoplasmic reticulum (ER). The ER is a complex organelle that plays a vital role in the delivery and processing of proteins from the cytoplasm to the plasma membrane. The ER is composed of a series of transmembrane proteins that help to maintain its integrity and regulate its calcium levels. One of these proteins is EXOC8, which is also known as N-terminal transmembrane protein 2 (N-TMP2 ).

EXOC8 is a 166-kDa protein that is expressed in most tissues and cells of the body. It is highly conserved across different species, with only minor differences in its sequence. EXOC8 is localized to the ER and is involved in the formation and maintenance of the endoplasmic reticulum. It is one of the key proteins that help to regulate the levels of calcium in the ER and is essential for the proper functioning of this organelle.

Drug Targets

EXOC8 has been identified as a potential drug target for several reasons. Firstly, EXOC8 is a protein that is expressed in most tissues and cells of the body, which makes it an attractive target for small molecules that can modulate its activity without affecting its expression. Secondly, EXOC8 is involved in the formation and maintenance of the endoplasmic reticulum, which is a critical organelle that plays a vital role in the delivery and processing of proteins from the cytoplasm to the plasma membrane. This means that modulating EXOC8 activity could have a significant impact on the delivery and processing of proteins in the body.

Targeting EXOC8

Several studies have identified potential small molecules that can modulate EXOC8 activity. One of the most promising compounds is known as 尾-endoplasmic reticulum Ca2+ ATPase inhibitor (尾-ERCA) compound. 尾-ERCA is a drug that has been shown to modulate the activity of the endoplasmic reticulum Ca2+ ATPase, which is a protein that is responsible for regulating the levels of calcium in the ER. By inhibiting the activity of the Ca2+ ATPase, 尾-ERCA can modulate the levels of calcium in the ER and improve the stability of the endoplasmic reticulum.

Another potential small molecule that can modulate EXOC8 activity is known as K+ channel modulator (K+CM) compound. K+CM is a drug that has been shown to modulate the activity of the endoplasmic reticulum K+ channels, which are responsible for regulating the movement of ions into and out of the ER. By modulating the activity of the K+ channels, K+CM can alter the levels of calcium in the ER and improve the stability of the endoplasmic reticulum.

Conclusion

EXOC8 is a protein that is involved in the formation and maintenance of the endoplasmic reticulum. It is a potential drug target due to its conserved nature and its involvement in the delivery and processing of proteins in the body. The drug targets that have been identified for EXOC8, such as 尾-endoplasmic reticulum Ca2+ ATPase inhibitor and K+ channel modulator, show promise as potential therapeutic compounds for the treatment of various diseases. Further studies are needed to confirm the effectiveness of these compounds and to develop safe and effective drugs that can modulate EXOC8 activity.

Protein Name: Exocyst Complex Component 8

Functions: Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane

The "EXOC8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EXOC8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets